AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 …
WEBJun 5, 2024 · UPLIZNA is currently approved for Neuromyelitis Optica Spectrum Disorder (NMOSD) by several regulatory bodies, including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and the Brazilian Health Regulatory Agency (ANVISA), among others.
Amgen's Uplizna posts strong results in myasthenia gravis trial
WEB2 days ago · Amgen Uplizna Myasthenia Gravis Horizon Therapeutics. Three months after Amgen revealed that Uplizna had aced a phase 3 trial in immunoglobulin G4-related disease (IgG4), the company said the anti ...
Amgen reports success for eczema and myasthenia gravis …
WEB3 days ago · In the Phase 3 trials, dubbed Horizon and Mint, the California company tested therapies for eczema and myasthenia gravis, respectively. In its eczema trial, Amgen reported that its drug ...
Amgen claims success for two immune drugs, but results …
WEB3 days ago · Uplizna is already approved for a different immune disease, and Amgen is hoping to expand its use. Amgen said it plans to use the latest results, which it termed potentially “practice-changing ...
Amgen Seeks Expanded US Approval For Autoimmune Disease …
WEBJun 5, 2024 · On Wednesday, Amgen Inc (NASDAQ: AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna (inebilizumab-cdon) for Immunoglobulin G4-related disease,...
Amgen’s Buy Rating Affirmed by Analyst Amid Potential of Uplizna …
WEB3 days ago · Amgen (AMGN) Company Description: Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture ...
Amgen Scores Late-Stage Wins in Eczema and Myasthenia Gravis, …
WEB2 days ago · Amgen on Tuesday announced dual Phase III victories, with its investigational antibody rocatinlimab demonstrating strong symptomatic improvement in atopic dermatitis and its anti-CD19 therapy Uplizna (inebilizumab-cdon) reducing flare risk in patients with generalized myasthenia gravis.. With Tuesday’s readouts, Amgen is working toward regulatory submissions for Uplizna in myasthenia gravis ...
Amgen preps Uplizna filing for a second indication
WEBJun 6, 2024 · Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, after positive results in...
Amgen's muscular disorder drug meets main goal in late-stage …
WEB3 days ago · View comments. (Reuters) -Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting ...
Amgen's Uplizna proves its worth in another rare disease, setting …
WEBJun 5, 2024 · The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon Therapeutics. Now, with a phase 3 triumph in progressive fibroinflammatory...
- Some results have been removed